동국생명과학

303810KOSDAQ의약품 제조업

63.3 / 100

Reference Date: 2026-07-24

Financial Score26.0 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly down 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dongkook Life Science is a specialized contrast agent manufacturer focusing on X-ray, CT, and MRI imaging diagnostics, with iodinated and gadolinium-based contrast agents as core products. Driven by aging populations and rising diagnostic demand, the company has expanded its market share to 22.6% in 2024. It is diversifying its portfolio through medical equipment distribution and AI medical device expansion.

Number of Employees

203people

Average Salary

64.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.71Industry Average 11.235.0Point

In line with industry avg

PBR

0.58Industry Average 0.815.5Point

Lower than industry avg (good)

ROE

7.32Industry Average 4.015.5Point

1.8x industry avg (good)

Debt Ratio

4.26Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2024~20253.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼1.1% (1-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲9.5% (1-year basis)

ROE Trend

1.0 / 4

Avg ROE 5.0% (improving, 2yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
[어바웃 C] 신태현 인벤테라 대표 특명 '첫 매출 시간표'
신태현 대표의 철 기반 MRI 조영제 NEMO-103주를 통한 내년 첫 매출 및 2028년 흑자전환 목표 발표로 동국생명과학의 미래 성장 기대감이 높아짐.
Positive
신태현 인벤테라 대표 “인비니티로 정밀진단 넘어 약물전달 치료제 ...
신태현 대표의 발표로 인벤테라의 혁신적인 나노의약품 기술이 정밀진단을 넘어 약물전달 분야로 확장될 것으로 예상되어 동국생명과학 관련 투자자들에게 긍정적 영향.
Positive
인벤테라, 가돌리늄 대체 MRI 조영제 상업화 주목-NH
인벤테라의 가돌리늄 대체 MRI 조영제 상업화 성공으로 동국생명과학 관련주에 긍정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 2,395Won52-week high 5,15052-week low 2,305

1-month return2.0Point

1m -2.64% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02